Rapid Elevation in CMPF May Act As a Tipping Point in Diabetes Development

Cell Reports

Volumn 14, Issue 12, 2016, Pages 2889-2900

  Liu, Ying ^a   Prentice, Kacey J ^a   Eversley, Judith A ^a   Hu, Cheng ^b   Batchuluun, Battsetseg ^a   Leavey, Katherine ^a   Hansen, Jakob B ^a   Wei, David W ^a   Cox, Brian ^a   Dai, Feihan F ^a   Jia, Weiping ^b   Wheeler, Michael B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 CARBOXY 4 METHYL 5 PROPYL 2 FURANPROPANOIC ACID; ADVANCED GLYCATION END PRODUCT; FURAN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPANOIC ACID; FURAN DERIVATIVE; GLUCOSE; INSULIN; PROPIONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; ADULT; AGED; ANIMAL; BLOOD; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIPID DIET; MALE; METABOLISM; MIDDLE AGED; PANCREAS; PATHOLOGY; STATISTICAL MODEL;

ADULT; AGED; ANIMALS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; FEMALE; FURANS; GENE EXPRESSION REGULATION; GLUCOSE; GLYCOLYSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN; INSULIN-SECRETING CELLS; LOGISTIC MODELS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; PANCREAS; PREDIABETIC STATE; PROPIONATES; REACTIVE OXYGEN SPECIES;

EID: 84961219488     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.079     Document Type: Article

References (46)

1. Abdul-Ghani M.A., DeFronzo R.A. Pathophysiology of prediabetes. Curr. Diab. Rep. 2009, 9:193-199.
2. Abdul-Ghani M.A., Tripathy D., DeFronzo R.A. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006, 29:1130-1139.
3. Allister E.M., Robson-Doucette C.A., Prentice K.J., Hardy A.B., Sultan S., Gaisano H.Y., Kong D., Gilon P., Herrera P.L., Lowell B.B., Wheeler M.B. UCP2 regulates the glucagon response to fasting and starvation. Diabetes 2013, 62:1623-1633.
4. Bansal N. Prediabetes diagnosis and treatment: a review. World J. Diabetes 2015, 6:296-303.
5. Bao Y., Ma X., Li H., Zhou M., Hu C., Wu H., Tang J., Hou X., Xiang K., Jia W. Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. BMJ 2010, 340:c2249.
6. Buchanan T.A., Xiang A.H. Gestational diabetes mellitus. J. Clin. Invest. 2005, 115:485-491.
7. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
8. Cheng K., Andrikopoulos S., Gunton J.E. First phase insulin secretion and type 2 diabetes. Curr. Mol. Med. 2013, 13:126-139.
9. Coughlan M.T., Yap F.Y., Tong D.C., Andrikopoulos S., Gasser A., Thallas-Bonke V., Webster D.E., Miyazaki J., Kay T.W., Slattery R.M., et al. Advanced glycation end products are direct modulators of β-cell function. Diabetes 2011, 60:2523-2532.
10. Diao J., Allister E.M., Koshkin V., Lee S.C., Bhattacharjee A., Tang C., Giacca A., Chan C.B., Wheeler M.B. UCP2 is highly expressed in pancreatic alpha-cells and influences secretion and survival. Proc. Natl. Acad. Sci. USA 2008, 105:12057-12062.
11. Ferrannini E., Nannipieri M., Williams K., Gonzales C., Haffner S.M., Stern M.P. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 2004, 53:160-165.
12. Ferrannini E., Gastaldelli A., Iozzo P. Pathophysiology of prediabetes. Med. Clin. North Am. 2011, 95:327-339. vii-viii.
13. Goehring I., Sauter N.S., Catchpole G., Assmann A., Shu L., Zien K.S., Moehlig M., Pfeiffer A.F., Oberholzer J., Willmitzer L., et al. Identification of an intracellular metabolic signature impairing beta cell function in the rat beta cell line INS-1E and human islets. Diabetologia 2011, 54:2584-2594.
14. Grill V., Dinesen B., Carlsson S., Efendic S., Pedersen O., Ostenson C.G. Hyperproinsulinemia and proinsulin-to-insulin ratios in Swedish middle-aged men: association with glycemia and insulin resistance but not with family history of diabetes. Am. J. Epidemiol. 2002, 155:834-841.
15. Hou J.C., Min L., Pessin J.E. Insulin granule biogenesis, trafficking and exocytosis. Vitam. Horm. 2009, 80:473-506.
16. Hull R.L., Westermark G.T., Westermark P., Kahn S.E. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 2004, 89:3629-3643.
17. Jonas J.C., Bensellam M., Duprez J., Elouil H., Guiot Y., Pascal S.M. Glucose regulation of islet stress responses and beta-cell failure in type 2 diabetes. Diabetes Obes. Metab. 2009, 11(Suppl 4):65-81.
18. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46:3-19.
19. Kaneto H., Xu G., Song K.H., Suzuma K., Bonner-Weir S., Sharma A., Weir G.C. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J. Biol. Chem. 2001, 276:31099-31104.
20. Kawamori D., Kajimoto Y., Kaneto H., Umayahara Y., Fujitani Y., Miyatsuka T., Watada H., Leibiger I.B., Yamasaki Y., Hori M. Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH(2)-terminal kinase. Diabetes 2003, 52:2896-2904.
21. Lindström P. Beta-cell function in obese-hyperglycemic mice [ob/ob mice]. Adv. Exp. Med. Biol. 2010, 654:463-477.
22. Luu L., Dai F.F., Prentice K.J., Huang X., Hardy A.B., Hansen J.B., Liu Y., Joseph J.W., Wheeler M.B. The loss of Sirt1 in mouse pancreatic beta cells impairs insulin secretion by disrupting glucose sensing. Diabetologia 2013, 56:2010-2020.
23. Malaisse W.J., Maggetto C., Leclercq-Meyer V., Sener A. Interference of glycogenolysis with glycolysis in pancreatic islets from glucose-infused rats. J. Clin. Invest. 1993, 91:432-436.
24. Mari A., Tura A., Natali A., Laville M., Laakso M., Gabriel R., Beck-Nielsen H., Ferrannini E. Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia 2010, 53:749-756. RISC Investigators.
25. Masini M., Marselli L., Bugliani M., Martino L., Masiello P., Marchetti P., De Tata V. Ultrastructural morphometric analysis of insulin secretory granules in human type 2 diabetes. Acta Diabetol. 2012, 49(Suppl 1):S247-S252.
26. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., Hu Z.X., Lin J., Xiao J.Z., Cao H.B., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
27. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr. Rev. 2008, 29:351-366.
28. Poitout V., Amyot J., Semache M., Zarrouki B., Hagman D., Fontés G. Glucolipotoxicity of the pancreatic beta cell. Biochim. Biophys. Acta 2010, 1801:289-298.
29. Prentice K.J., Luu L., Allister E.M., Liu Y., Jun L.S., Sloop K.W., Hardy A.B., Wei L., Jia W., Fantus I.G., et al. The furan fatty acid metabolite CMPF is elevated in diabetes and induces β cell dysfunction. Cell Metab. 2014, 19:653-666.
30. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J. Clin. Invest. 2006, 116:1802-1812.
31. Robson-Doucette C.A., Sultan S., Allister E.M., Wikstrom J.D., Koshkin V., Bhattacharjee A., Prentice K.J., Sereda S.B., Shirihai O.S., Wheeler M.B. Beta-cell uncoupling protein 2 regulates reactive oxygen species production, which influences both insulin and glucagon secretion. Diabetes 2011, 60:2710-2719.
32. Sempoux C., Guiot Y., Dubois D., Moulin P., Rahier J. Human type 2 diabetes: morphological evidence for abnormal beta-cell function. Diabetes 2001, 50(Suppl 1):S172-S177.
33. Shankar R.R., Zhu J.S., Baron A.D. Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus. Metabolism 1998, 47:573-577.
34. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products: a review. Diabetologia 2001, 44:129-146.
35. Spégel P., Sharoyko V.V., Goehring I., Danielsson A.P., Malmgren S., Nagorny C.L., Andersson L.E., Koeck T., Sharp G.W., Straub S.G., et al. Time-resolved metabolomics analysis of β-cells implicates the pentose phosphate pathway in the control of insulin release. Biochem. J. 2013, 450:595-605.
36. Syed I., Kyathanahalli C.N., Jayaram B., Govind S., Rhodes C.J., Kowluru R.A., Kowluru A. Increased phagocyte-like NADPH oxidase and ROS generation in type 2 diabetic ZDF rat and human islets: role of Rac1-JNK1/2 signaling pathway in mitochondrial dysregulation in the diabetic islet. Diabetes 2011, 60:2843-2852.
37. Tang J., Neidigh J.L., Cooksey R.C., McClain D.A. Transgenic mice with increased hexosamine flux specifically targeted to beta-cells exhibit hyperinsulinemia and peripheral insulin resistance. Diabetes 2000, 49:1492-1499.
38. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001, 344:1343-1350. Finnish Diabetes Prevention Study Group.
39. Uchizono Y., Alarcón C., Wicksteed B.L., Marsh B.J., Rhodes C.J. The balance between proinsulin biosynthesis and insulin secretion: where can imbalance lead?. Diabetes Obes. Metab. 2007, 9(Suppl 2):56-66.
40. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1994, 91:4766-4770.
41. Wang C.Y., Liao J.K. A mouse model of diet-induced obesity and insulin resistance. Methods Mol. Biol. 2012, 821:421-433.
42. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 53(Suppl 3):S16-S21.
43. Weir G.C., Marselli L., Marchetti P., Katsuta H., Jung M.H., Bonner-Weir S. Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes. Diabetes Obes. Metab. 2009, 11(Suppl 4):82-90.
44. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 1999, 104:787-794.
45. Wikstrom J.D., Sereda S.B., Stiles L., Elorza A., Allister E.M., Neilson A., Ferrick D.A., Wheeler M.B., Shirihai O.S. A novel high-throughput assay for islet respiration reveals uncoupling of rodent and human islets. PLoS ONE 2012, 7:e33023.
46. Zhang Z., Liew C.W., Handy D.E., Zhang Y., Leopold J.A., Hu J., Guo L., Kulkarni R.N., Loscalzo J., Stanton R.C. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis. FASEB J. 2010, 24:1497-1505.